Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 14NIH 2INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Anemia 116Neoplasms 77Anemia, Refractory, with Excess of Blasts 32Myelodysplastic Syndromes 31Leukemia, Myeloid, Acute 28Venous Thromboembolism 25Thrombocytopenia 24Leukemia 22Breast Neoplasms 22Febrile Neutropenia 21Neutropenia 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 17Multiple Myeloma 15Lymphoma 14Hematologic Neoplasms 14Anemia, Sickle Cell 14Ovarian Neoplasms 12Myeloproliferative Disorders 10Leukemia, Lymphocytic, Chronic, B-Cell 10Fanconi Anemia, Complementation Group D1 10Venous Thrombosis 9Primary Myelofibrosis 9Lung Neoplasms 9Leukemia, Myelomonocytic, Chronic 9Prostatic Neoplasms 8Lymphoma, Non-Hodgkin 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Hodgkin Disease 8Pulmonary Embolism 7Hemophilia A 7

Interventions

ravulizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hemoglobinuria, Paroxysmal × Classical hematology × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔